NO20084688L - lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser - Google Patents
lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelserInfo
- Publication number
- NO20084688L NO20084688L NO20084688A NO20084688A NO20084688L NO 20084688 L NO20084688 L NO 20084688L NO 20084688 A NO20084688 A NO 20084688A NO 20084688 A NO20084688 A NO 20084688A NO 20084688 L NO20084688 L NO 20084688L
- Authority
- NO
- Norway
- Prior art keywords
- independently
- linker
- compounds
- raf
- pyridin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- JXXWJMUPNZDILL-UHFFFAOYSA-N imidazo[4,5-b]pyridin-2-one Chemical compound C1=CC=NC2=NC(=O)N=C21 JXXWJMUPNZDILL-UHFFFAOYSA-N 0.000 title abstract 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 239000012830 cancer therapeutic Substances 0.000 title 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title 1
- 125000005647 linker group Chemical group 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 abstract 2
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000005488 carboaryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- OVLXOTUWFLHWQT-UHFFFAOYSA-N oxazolo[4,5-b]pyridin-2(3H)-one Chemical class C1=CC=C2OC(=O)NC2=N1 OVLXOTUWFLHWQT-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74563306P | 2006-04-26 | 2006-04-26 | |
| GBGB0608268.9A GB0608268D0 (en) | 2006-04-26 | 2006-04-26 | Therapeutic compounds |
| PCT/GB2007/001534 WO2007125330A1 (en) | 2006-04-26 | 2007-04-26 | Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20084688L true NO20084688L (no) | 2009-01-26 |
Family
ID=38421488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084688A NO20084688L (no) | 2006-04-26 | 2008-11-06 | lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7951819B2 (https=) |
| EP (1) | EP2013207B1 (https=) |
| JP (1) | JP2009534457A (https=) |
| AU (1) | AU2007245495A1 (https=) |
| CA (1) | CA2649994A1 (https=) |
| NO (1) | NO20084688L (https=) |
| WO (1) | WO2007125330A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073513A1 (en) * | 2007-11-30 | 2009-06-11 | Schering Corporation | Braf biomarkers |
| AU2008337286B2 (en) * | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0807609D0 (en) * | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| NZ601085A (en) | 2010-02-01 | 2015-04-24 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| CA2797237C (en) | 2010-04-21 | 2018-05-22 | The Regents Of The University Of Michigan | Fluoroscopy-independent, endovascular aortic occlusion system |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| WO2013022766A1 (en) * | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| US9474882B2 (en) | 2013-02-26 | 2016-10-25 | Prytime Medical Devices, Inc. | Fluoroscopy-independent balloon guided occlusion catheter and methods |
| CA2923419A1 (en) | 2013-09-09 | 2015-03-12 | Pryor Medical Devices, Inc. | Low-profile occlusion catheter |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| AU2015274743B2 (en) | 2014-06-10 | 2016-11-10 | Prytime Medical Devices, Inc. | Conduit guiding tip |
| JP6472536B2 (ja) | 2015-03-19 | 2019-02-20 | プリタイム・メディカル・デバイシーズ・インコーポレイテッドＰｒｙｔｉｍｅ Ｍｅｄｉｃａｌ Ｄｅｖｉｃｅｓ，Ｉｎｃ． | 低プロファイル閉塞バルーンカテーテル用のシステムおよび方法 |
| EP3463106B1 (en) | 2016-06-02 | 2023-10-25 | Prytime Medical Devices, Inc. | System for low profile occlusion balloon catheter |
| AU2017312970B2 (en) * | 2016-08-16 | 2021-08-12 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof |
| EP3568190B1 (en) | 2017-01-12 | 2023-11-22 | The Regents of the University of California | Endovascular perfusion augmentation for critical care |
| PL3601233T3 (pl) | 2017-03-27 | 2025-01-07 | HYDRO-QUéBEC | Sole do zastosowania w kompozycjach elektrolitowych lub jako dodatki do elektrod |
| CN110769749B (zh) | 2017-04-21 | 2023-05-09 | 加利福尼亚大学董事会 | 用于部分主动脉闭塞的主动脉流量计和泵 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| US12011172B2 (en) | 2018-08-06 | 2024-06-18 | Prytime Medical Devices, Inc. | Occlusion catheter system for full or partial occlusion |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| PH12022550298A1 (en) | 2019-08-08 | 2023-04-24 | B C I Pharma | Quinoline derivatives as protein kinase inhibitors |
| PT4013412T (pt) | 2019-08-12 | 2026-03-18 | Deciphera Pharmaceuticals Llc | Ripretinib para o tratamento de tumores estromais gastrointestinais |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| CN112574176B (zh) * | 2019-09-27 | 2024-03-15 | 隆泰申医药科技(南京)有限公司 | 一种杂芳基类化合物及其应用 |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| JP7835406B2 (ja) | 2020-03-16 | 2026-03-25 | サータス クリティカル ケア， インコーポレイテッド | 血流制御デバイス、システム、及び方法、並びにそれらのエラー検出 |
| US11629143B2 (en) | 2020-10-01 | 2023-04-18 | Vibliome Therapeutics, Llc | HipK4 inhibitors and uses thereof |
| US12102330B2 (en) | 2021-03-18 | 2024-10-01 | Prytime Medical Devices, Inc. | Vascular occlusion catheter for partial occlusion or full occlusion |
| TWI812301B (zh) * | 2021-06-24 | 2023-08-11 | 南韓商Ｌｇ化學股份有限公司 | 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| EP4622971A1 (en) | 2022-11-24 | 2025-10-01 | B.C.I. Pharma | Pyridine derivatives as protein kinase inhibitors |
| WO2025021943A1 (en) | 2023-07-26 | 2025-01-30 | Neuralis | Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5665863A (en) | 1979-10-31 | 1981-06-03 | Tokyo Organ Chem Ind Ltd | Novel aniline derivative, its preparation and pesticide containing the same |
| JPS5738777A (en) | 1980-08-19 | 1982-03-03 | Sogo Yatsukou Kk | 2-sufanilamidopyrathyn derivative |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| DE69534180T2 (de) | 1994-09-22 | 2006-03-02 | Licentia Ltd. | Promotor der tie rezeptor protein kinase |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| NZ503432A (en) | 1997-09-26 | 2002-11-26 | Zentaris Gmbh | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| GB2356398A (en) | 1999-11-18 | 2001-05-23 | Lilly Dev Ct S A | Preparation of arylsulfamides |
| WO2001046196A1 (en) | 1999-12-21 | 2001-06-28 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| AU2002232439A1 (en) | 2000-11-29 | 2002-06-11 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| NZ532780A (en) | 2001-12-21 | 2006-10-27 | Wellcome Trust | Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them |
| US20060128783A1 (en) | 2002-08-09 | 2006-06-15 | Dinsmore Christopher J | Tyrosine kinase inhibitors |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| BRPI0514691A (pt) * | 2004-08-31 | 2008-06-17 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
-
2007
- 2007-04-26 AU AU2007245495A patent/AU2007245495A1/en not_active Abandoned
- 2007-04-26 US US12/298,325 patent/US7951819B2/en not_active Expired - Fee Related
- 2007-04-26 EP EP07732571A patent/EP2013207B1/en active Active
- 2007-04-26 CA CA002649994A patent/CA2649994A1/en not_active Abandoned
- 2007-04-26 WO PCT/GB2007/001534 patent/WO2007125330A1/en not_active Ceased
- 2007-04-26 JP JP2009507165A patent/JP2009534457A/ja active Pending
-
2008
- 2008-11-06 NO NO20084688A patent/NO20084688L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007125330A1 (en) | 2007-11-08 |
| JP2009534457A (ja) | 2009-09-24 |
| CA2649994A1 (en) | 2007-11-08 |
| US20090325945A1 (en) | 2009-12-31 |
| US7951819B2 (en) | 2011-05-31 |
| EP2013207A1 (en) | 2009-01-14 |
| AU2007245495A1 (en) | 2007-11-08 |
| EP2013207B1 (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084688L (no) | lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser | |
| JP7554300B2 (ja) | 大環式化合物およびその使用 | |
| NO20072546L (no) | Imidazo[4,5-b]pyridin-2-on og oksazolo[4,5-B]pyridin-2-on forbindelser og analoger derav som terapeutiske forbindelser | |
| Casini et al. | Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects | |
| EP3421039B1 (en) | Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor | |
| ES2517690T3 (es) | Quinazolinona, quinolona y análogos relacionados como moduladores de sirtuina | |
| ES2661367T3 (es) | Inhibidores de cinasa CDC7 y sus usos | |
| WO2006067466A3 (en) | Pyrazines and pyridines and derivatives thereof as therapeutic compounds | |
| CN109069504B (zh) | 氨基噻唑化合物及其用途 | |
| US11365189B2 (en) | Heterocyclic inhibitors of tyrosine kinase | |
| JP2020514409A (ja) | ジアリール大環状化合物を含む併用療法 | |
| NO20084927L (no) | Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem | |
| NO20074274L (no) | Tetrahydroindolon og tetrahydroindazolonderivater | |
| CN103224496B (zh) | 三环类PI3K和/或mTOR抑制剂 | |
| KR20110098789A (ko) | 시르투인 조절제로서의 이소인돌리논 및 관련 유사체 | |
| JP7641965B2 (ja) | 疾患処置に使用するための大環状分子 | |
| Mroueh et al. | Unmasking the interplay between mTOR and Nox4: novel insights into the mechanism connecting diabetes and cancer | |
| JP2013129632A (ja) | Ｅｎｐｐ２阻害化合物 | |
| WO2011019943A1 (en) | Method of promoting apoptosis and inhibiting metastasis | |
| JP2010535211A (ja) | 炎症性障害、脱髄障害および癌を治療するためのインダゾール化合物 | |
| BRPI0614456B1 (pt) | 8-metoxi-9h-isotiazol[5,4-b]quinolina-3,4-dionas e compostos relacionados como agentes antiinfecciosos | |
| KR20100031759A (ko) | 흑색종의 치료 | |
| US20180201640A1 (en) | 4-methylumbelliferone derivatives for treatment for immune modulation | |
| WO2024173761A1 (en) | Combinations comprising mek inhibitors for use in the treatment of cancer | |
| EP1684747B1 (en) | Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |